| pubmed-article:9250793 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9250793 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9250793 | lifeskim:mentions | umls-concept:C0024305 | lld:lifeskim |
| pubmed-article:9250793 | lifeskim:mentions | umls-concept:C0092801 | lld:lifeskim |
| pubmed-article:9250793 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:9250793 | lifeskim:mentions | umls-concept:C1282907 | lld:lifeskim |
| pubmed-article:9250793 | lifeskim:mentions | umls-concept:C0021440 | lld:lifeskim |
| pubmed-article:9250793 | lifeskim:mentions | umls-concept:C1522326 | lld:lifeskim |
| pubmed-article:9250793 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:9250793 | pubmed:dateCreated | 1997-9-26 | lld:pubmed |
| pubmed-article:9250793 | pubmed:abstractText | The purpose of our study was to determine the efficacy of 2-chlorodeoxyadenosine (2-CdA) administered in 2-hour intravenous infusions in previously treated patients with low grade non-Hodgkin's lymphoma (LGNHL). We treated 94 LGNHL patients with 2-CdA at a dosage of 0.12 mg/kg/24h in 2-hour intravenous infusion for 5 consecutive days. The treatment consisted of from 1 to 7 courses (median 3), repeated usually at monthly intervals. All patients were refractory to or relapsed after standard chemotherapy. Of these 94 patients 78 (83%) had clinical stage IV of the disease. Complete response (CR) was obtained in 12 (12.8%) and partial response (PR) in 36 (38.3%) giving an overall response rate of 51.1%. In 12 (12.8%) grade 4 thrombocytopenia with haemorrhagic diathesis was noted, grade 4 neutropenia was observed in 12 (12.8%) and infections complicated the course of treatment in 38 (40.4%) patients. 2-CdA treatment was the cause of death of 3 patients. The results of our study show that 2-CdA given in 2-hour infusions is an effective agent in advanced, heavily pretreated patients with LGNHL. | lld:pubmed |
| pubmed-article:9250793 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9250793 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9250793 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9250793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9250793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9250793 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9250793 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:9250793 | pubmed:issn | 1042-8194 | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:HellmannAA | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:GriebPP | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:Dmoszy?skaAA | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:KonopkaLL | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:KrykowskiEE | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:Dwilewicz-Tro... | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:MajSS | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:KuratowskaZZ | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:DerenMM | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:MichalakKK | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:Adamczyk-Cioc... | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:SikorskaAA | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:WalewskiJ AJA | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:ZauchaJ MJM | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:PotemskiPP | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:BoguradzkiPP | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:CeglarekBB | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:RóbakTT | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:Gora-TyborJJ | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:BorawskaAA | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:Plu?a?skaAA | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:Dur?y?skiTT | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:Urasi?skiJJ | lld:pubmed |
| pubmed-article:9250793 | pubmed:author | pubmed-author:Opali?skaJJ | lld:pubmed |
| pubmed-article:9250793 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9250793 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:9250793 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9250793 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9250793 | pubmed:pagination | 99-105 | lld:pubmed |
| pubmed-article:9250793 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:9250793 | pubmed:meshHeading | pubmed-meshheading:9250793-... | lld:pubmed |
| pubmed-article:9250793 | pubmed:meshHeading | pubmed-meshheading:9250793-... | lld:pubmed |
| pubmed-article:9250793 | pubmed:meshHeading | pubmed-meshheading:9250793-... | lld:pubmed |
| pubmed-article:9250793 | pubmed:meshHeading | pubmed-meshheading:9250793-... | lld:pubmed |
| pubmed-article:9250793 | pubmed:meshHeading | pubmed-meshheading:9250793-... | lld:pubmed |
| pubmed-article:9250793 | pubmed:meshHeading | pubmed-meshheading:9250793-... | lld:pubmed |
| pubmed-article:9250793 | pubmed:meshHeading | pubmed-meshheading:9250793-... | lld:pubmed |
| pubmed-article:9250793 | pubmed:meshHeading | pubmed-meshheading:9250793-... | lld:pubmed |
| pubmed-article:9250793 | pubmed:meshHeading | pubmed-meshheading:9250793-... | lld:pubmed |
| pubmed-article:9250793 | pubmed:meshHeading | pubmed-meshheading:9250793-... | lld:pubmed |
| pubmed-article:9250793 | pubmed:meshHeading | pubmed-meshheading:9250793-... | lld:pubmed |
| pubmed-article:9250793 | pubmed:meshHeading | pubmed-meshheading:9250793-... | lld:pubmed |
| pubmed-article:9250793 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9250793 | pubmed:articleTitle | Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma. | lld:pubmed |
| pubmed-article:9250793 | pubmed:affiliation | Department of Hematology, Medical University of Lód?, Poland. | lld:pubmed |
| pubmed-article:9250793 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9250793 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9250793 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
